Methadone is often invoked for detoxification and maintenance of the opioid addict. We have developed and validated a sensitive and specific method for the analysis of methadone and its metabolites, 2-ethylidene-t,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3- Methadone, a phenylheptylamine that has been described as one of the most widely used opioid analgesics, was first used to treat heroin addicts in 1965 (1). The mild withdrawal signs and symptoms that occur after abrupt discontinuation of methadone make this drug a useful medication for detoxification and maintenance of long-term, relapsing heroin addicts. The rationale for methadone maintenance depends on the capability of methadone to block the reinforcement from abuse of illicit opioids, thereby releasing the anxiety to obtain the drugs. This allows the clinician to treat these opiate-dependent individuals with psychiatric and rehabilitative therapy (2). It is necessary to maintain blood concentrations of methadone within an effective range to accomplish optimum treatment of these patients (3,4). Drug interactions may alter the metabolism of methadone, thereby interfering with methadone maintenance (5,6). It is necessary to have analytical methods that can quantitate methadone and its N-demethylated metabolites, 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyrroline (EMDP), to further explore the metabolism of methadone and factors that may modify its metabolism. Various techniques have been reported for determination of methadone and its metabolites in biological fluids, such as high-performance liquid chromatography (7-9); gas chromatography (5); and gas chromatography-mass spectrometry (GC-MS) (10-12). Few of these techniques have been characterized in sufficient detail to determine if they have adequate sensitivity, precision, and accuracy to support studies on methadone metabolism.
Methadone, a phenylheptylamine that has been described as one of the most widely used opioid analgesics, was first used to treat heroin addicts in 1965 (1) . The mild withdrawal signs and symptoms that occur after abrupt discontinuation of methadone make this drug a useful medication for detoxification and maintenance of long-term, relapsing heroin addicts. The rationale for methadone maintenance depends on the capability of methadone to block the reinforcement from abuse of illicit opioids, thereby releasing the anxiety to obtain the drugs. This allows the clinician to treat these opiate-dependent individuals with psychiatric and rehabilitative therapy (2) . It is necessary to maintain blood concentrations of methadone within an effective range to accomplish optimum treatment of these patients (3, 4) . Drug interactions may alter the metabolism of methadone, thereby interfering with methadone maintenance (5, 6) . It is necessary to have analytical methods that can quantitate methadone and its N-demethylated metabolites, 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyrroline (EMDP), to further explore the metabolism of methadone and factors that may modify its metabolism. Various techniques have been reported for determination of methadone and its metabolites in biological fluids, such as high-performance liquid chromatography (7-9); gas chromatography (5); and gas chromatography-mass spectrometry (GC-MS) (10) (11) (12) . Few of these techniques have been characterized in sufficient detail to determine if they have adequate sensitivity, precision, and accuracy to support studies on methadone metabolism.
In the present study, a gas chromatographic-positive ion chemical ionization-mass spectrometric (GC-PICI-MS) method has been developed to determine the concentrations of methadone, EDDP, and EMDP in different biological fluids such as human plasma, urine, and liver microsomes. Solidphase extraction for the isolation of these three analytes from the specimens studied is also described. We improved the sensitivity and selectivity of previously described GC-MS methods (10) (11) (12) by using PICI as a method of ionization and solidphase extraction as an efficient isolation procedure. Valida-tion of this method is described along with examples of its use to quantitate these compounds in human fluids and tissue.
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Materials and Methods

Materials
Methadone, EDDP, EMDP, EDDP-d3, and EMDP-d3 were obtained from Research Triangle Institute (Research Triangle Park, NC). Methadone-d 3 was purchased from Radian (Austin, TX). GC-GC-MS-grade methanol, methylene chloride, n-butyl chloride, and isopropyl alcohol were purchased from Baxter, B&J (Muskegon, MI). Analytical-grade concentrated ammonium hydroxide, dibasic and monobasic potassium phosphate, potassium hydroxide, and acetic acid were obtained from Mallinckrodt (Chesterfield, MO). The solid-phase extraction columns (Bond Elut Certify| size, 10 mL/130 mg; type, LRC) were purchased from Varian (Harbor City, CA). The GC column used was an HP-1 cross-linked methyl siloxane capillary column (25 m x 0.32-ram i.d., 0.17-~m film thickness) from Hewlett-Packard Analytical (Wilmington, DE). Human plasma was obtained from the University of Utah Blood Bank (Salt Lake City, UT). Human liver microsomes were obtained from 
Standards
Stock standards (deuterated and nondeuterated) of methadone, EDDP, and EMDP were first prepared as individual solutions containing I mg/mL in methanol. Aliquots of the three nondeuterated solutions were combined and diluted with methanol to obtain working solutions of 0.1, 1.0, and 10 tJg/mL of each analyte. Individual aliquots from these working solutions were added to 1-mL aliquots of drug-free plasma or urine to prepare calibrators at 10 to 600 ng/mL for each analyte. Aliquots of the three deuterated solutions were combined and diluted with methanol to provide a working internal standard solution containing each internal standard at a concentration of 1 IJg/mL. Refrigerated working solutions were stable for at least 90 days. A similar procedure was used to make quality control samples, except that separate weighings were used to prepare the stock solutions. Controls were then prepared at 25, 100, and 300 ng/mL of each analyte in the appropriate matrix, and 1-mL aliquots were stored at -20~ until analysis.
Extraction
The internal standard (100 IlL of a 1-~g/mL methanolic solution of methadone-d3, EDDP-d3, and EMDP-d3) was added to each 1-mL aliquot of sample, calibrator, and quality control in silanized 100-x 16-mm extraction tubes. The tubes were briefly vortex mixed and allowed to equilibrate for 30--45 min. Four milliliters of deionized water and 2 mL of 100raM phosphate buffer (pH 6.0)-methanol (80:20, v/v) were added to each tube; the tubes were vortex mixed briefly and centrifuged at 2000 rpm for 10-15 min. The supernatant was decanted into a clean tube. The pH of the supernatant was adjusted to 6.0 + 0.1 with 100raM monobasic or dibasic potassium phosphate. Solid-phase extraction columns were conditioned with 3 mL of methanol followed by 3 mL of deionized water and 1 mL of 100mM potassium phosphate buffer (pH 6.0). Care was taken to ensure that the columns did not dry between conditioning steps. The supernatants were loaded onto individual conditioned columns set in a vacuum manifold, and the vacuum was maintained at 3 in. Hg or more. After the samples were drawn through the columns, the cartridges were washed with 2 mL of deionized water, 2 mL of 100mM acetic acid, and 3 mL of methanol. The columns were dried under vacuum (5 min at 10 in. Hg or more). The analytes were then eluted with 3 mL of freshly prepared methylene chloride-isopropyl alcohol- 
Finnigan MAT) with crimp-capped vials. The peak areas and heights of the monitored ions were automatically calculated by the Incos data system. Peak-height ion ratios for rn/z 264/267, 278/281, and 310/313 were used to calculate concentrations of EMDP, EDDP, and methadone, respectively. Calibrators (in plasma and urine matrices) run with each batch were used to generate the calibration curve, which was calculated using the least-squares equation. Human liver microsomes were analyzed using plasma as a calibrator matrix.
GC-PICI-MS
Separations were performed with a Finnigan model 9610 GC equipped with an HP-1 column. High-purity hydrogen served as the carrier gas (linear velocity, approximately 80 crrgs). The initial column temperature of 80~ was held for 0.5 rnin, then increased to 280~ at a rate of 20~ and held for 1 rain. The injector temperature and the interface oven temperature were maintained at 260~ and 265~ respectively. Injections were performed in the splitless mode.
A Finnigan 4500 quadrupole MS was operated in the positive ion detection mode with methane-ammonia (4:1) as the reagent gas. The ion source temperature Calibrator setting was maintained at 130~ The elecmatrix tron multiplier was operated at 1400V, and Human urine the conversion @node was operated at 2 kV. Selected ion monitoring centroid data were collected. A Finnigan Super Incos data system was used to set the mass spectromHuman plasma eter to monitor the ion currents at m/z 264 and 267, m/z 278 and 281, and m/z 310 and 313, which correspond to the nondeuterated (do) and deuterated (d3) protonated molecules (MH § for EMDP, EDDP, and methadone, respectively. Injections of 1.0-1JL aliquots from each extract were performed using an autosampler (CTC AS 200;
Results and Discussion
Ionization, chromatography, and extraction
Positive ion chemical ionization with methane-ammonia provided clean mass spectra of methadone, EDDP, and EMDP that consisted of intense protonated molecular ions (MH § at m/z 310, 278, and 264 ( Figure 1 ). The corresponding protonated molecules for the trideuterated internal standards occurred at * Curve equations were calculated from least-squares regression analysis of peak-height ratios (dffd i) on the x-axis and concentration on the y-axis. For normal quantitation, low (5 lowest calibrators) and high (5 highest calibrators) calibration curves were generated. The intercept is given for the low curve to demonstrate deflection at the low end. The slope and coefficient of determination (r2) are given for the full curve to demonstrate linearity characteristics. r EDDP = 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine. * EMDP = 2-ethyl-5-methyl-3,3-diphenylpyrroline.
m/z 313, 281, and 267, respectively. No significant fragment ions were observed above m/z 100. Initial attempts to analyze methadone and its metabolites by derivatization were unsatisfactory. Methadone and its two major metabolites have no functional groups that are easy to derivatize. However, co-injection 
The I O-ng/mL samples are the limit of the quantitation calibrator. Human liver microsomes were analyzed using plasma as the calibrator matrix, so accuracy and precision at I0 nglml were not determined for microsomes. tl In the human liver microsome experiments, methadone was added as the substrate, and the measurement of low concentrations was not required. Only the medium and high quality controls were evaluated. * Values are from the mean and standard deviation of average values (n = analytical runs. * EDDP = 2-ethy]idene-t,5-dimethyl-3,3-diphenylpyrrolidine. * EMDP = 2-ethyl-5-methyl-3,3-diphenylpyrroline.
or 5 per run) of three separate
The I O-nglmL samples are the limit of the quantitation calibrator. Human liver microsomes were analyzed using plasma as the calibrator matrix, so accuracy and precision at I 0 ng/mL were not determined for microsomes. tl In the human liver microsome experiments, methadone was added as the substrate, and the measurement of low concentrations was not required. Only the medium and high quality controls were evaluated.
Recovery
The extraction recovery of the analytes was determined from a comparison of the ratio of peak heights (d0/d3) of control samples at 25, 100, and 300 ng/mL. Two sets of samples (A and B; n = 5 for each set) for plasma, urine, and microsomes (for microsomes only, a 100-ng/mL control was used) were prepared. The deuterated internal standard was added to all samples before solid-phase extraction, whereas the nondeuterated methadone, EMDP, and EDDP standards were added to set A before extraction and to set B after solid-phase extraction. The ratios of the analyte peak heights to the corresponding internal standard peak heights were determined, and percent recovery was calculated by dividing the mean ratio for set A by the mean ratio for the corresponding set B and multiplying by 100% (Table I ). The amounts recovered for methadone, EDDP, and EMDP ranged from 85 to 107% in urine, from 90 to 105% in plasma, and from 85 to 99% in liver microsomes.
Linearity
The linear dynamic range of the assay for the three analytes studied was established for plasma and urine calibrators from 10 to 600 ng/mL. Methadone, EDDP, and EMDP were detectable in calibrators at concentrations of 5 ng/mL; however, the accuracy and precision of the quantitation of the calibrators did not reach acceptable criteria for a limit of quantitation (LOQ) until the concentration was increased to 10 ng/mL. Coefficients of determination (r 2) for methadone, EDDP, and EMDP were 0.995-0.999 in urine and 0.994-0.997 in plasma (Table II) . These r 2 values indicated a satisfactory linear relationship between the peak-height ratios (do/d3) and the concentration of each analyte up to 600 ng/mL.
400
Accuracy and precision
Intra-assay and interassay accuracy and precision for the analysis of methadone, EDDP, and EMDP were determined at 10 ng/mL, at the LOQ, and at 25, 100, and 300 ng/mL (Tables III and  IV) . The intra-assay accuracy and precision were determined from a batch in which the controls were run with an N value of 5 (Table III) . The intra-assay coefficient of variation (% CV) for methadone, EDDP, and EMDP ranged from 4.2 to 12.3% for human urine, from 2.0 to 8.8% for human plasma, and from 1.2 to 10.6% for human liver microsomes. For interassay studies, batches were run on three separate days. In two batches, each control was analyzed in triplicate, and in one batch, each control was analyzed in quintuplicate. The interassay % CV values for methadone, EDDP, and EMDP ranged from 2.2 to 9.5% for human urine, from 0.8 to 15.0% for human plasma, and from 2.7 to 14.7% for human liver microsomes (Table IV) . These values demonstrated that the method was precise and accurate through the linear dynamic range used for urine, plasma, and liver microsomes. The LOQ of 10 ng/mL was an improvement over previously reported assays (11, 12) .
Stability
The stability of methadone, EDDP, and EMDP in urine, plasma, and liver microsome quality controls (at 300 ng/mL; n = 3) was determined after storage at room temperature for 0, 3, 6, and 24 h and after 1 week for plasma and urine. The effect of two cycles of freezing and thawing was also determined. Results from these experiments (Figure 3 ) demonstrate that there were no statistically significant changes in concentrations over the period of the study, which suggested that methadone, EDDP, and EMDP are stable in these biological specimens under those storage conditions.
Application of the method
For many years methadone has been used to treat opiate addiction. Monitoring the concentrations of methadone, EDDP, and EMDP in biological specimens provides valuable information on the pharmacokinetics of this drug; the information allows physicians to vary the dosing schedule according to the needs and responses of the patients under treatment. Plasma and urine specimens are also collected from medicolegal cases and are referred to the forensic laboratory for the analysis of abused substances. Occasionally, determination of the concentration of methadone or its metabolites or both is necessary. Table V shows the concentration of methadone, EDDP, and EMDP in methadone-positive plasma and urine specimens submitted to this center for toxicological analysis. Methadone concentrations in the plasma specimens ranged from 33 to 358 ng/mL. In general, the first N-demethylation metabolite, EDDP, was not detected until methadone concentrations exceeded 118 ng/mL; thereafter, the EDDP concentration increased with methadone. There were, however, exceptions; EDDP was detected in one specimen in which the methadone concentration was 88 ng/mL and not detected in a specimen in which the methadone concentration was 150 ng/mL. In the 15 specimens in which both methadone and EDDP were detected, the ratio of methadone to EDDP ranged from 5.6 to 15.1 (mean plus or minus standard deviation [SD], 11.9 • 2.6). The second metabolite, EMDP, was not detected at concentrations exceeding 10 ng/mL in any of the plasma specimens. To the best of our knowledge, plasma concentrations of EDDP and EMDP in humans have not been previously reported. It is of interest, however, that these ratios of plasma concentrations of methadone to metabolites are consistent with the ratios found in the hair of two humans and three rats treated with methadone (13). <10  58  <10  <10  88  11  <10  91  <10  <10  101  <10  <10  102  <10  <10  103  <10  <10  118  11  <10  20  22  <10  50  <10  <10  52  11  <10  54  13  <10  67  14  <10  72  14  <10  79  13  <10  84  17  <10  202  19  <10  234  19  <10  257  17  <10  258  20  <10  287  20  <10  358  24  <10   126  3600  <10  1600  12910  32  2650  10392  33  2903  12126  33  3873 5444 <10
In the five urine specimens analyzed, methadone concentrations ranged from 126 to 3873 ng/mL. In contrast to plasma, urine EDDP concentrations were consistently greater than methadone, such that the urine methadone to EDDP ratios ranged from 0.04 to 0.71 (mean • SD, 0.27 • 0.26). Low concentrations of EMDP (from 32 to 33 ng/mL) were detected in the three urine specimens that had the highest EDDP concentrations. The large difference in methadone and EDDP concentrations versus EMDP concentrations had an operational impact on urine analysis; we found it was necessary to perform two analyses to maintain the concentrations of the three compounds in the dynamic range of the calibration curve. An undiluted sample was monitored for EMDP, whereas a diluted sample (usually 1:9) was monitored for methadone and EDDP.
Sullivan and Due (10) reported the concentrations of methadone, EDDP, and EMDP in urine collected in 24 h. They found that ratios of urine methadone to EDDP were 2.5, 1.3, and 0.4 and that EMDP concentrations were significantly lower than either methadone or EDDP concentrations. As we have neither the dose of methadone nor the timing of specimen collection for the specimens we analyzed, it is difficult to compare these results in a meaningful fashion. The differences between the plasma and urine ratios of methadone to EDDP do, however, suggest that EDDP has a much greater renal clearance than methadone. Using our analytical method in a structured pharmacokinetic study could provide more information on the variation of methadone and its N-demethylation metabolites over time. Another important use of the method would be the detection of large shifts in the ratio of methadone to EDDP that may occur if methadone metabolism is altered through induction or inhibition of the enzyme(s) responsible for methadone N-demethylation.
It will be meaningful to obtain more information about the specific drug-metabolizing enzymes involved in methadone metabolism so that potential drug interactions or genetic deficiencies in the human metabolism of methadone can be studied. The capability of the method to detect N-demethylated metabolites from methadone was studied by incubating human liver microsomes with methadone and a reduced NADPHgenerating system (Figure 4) . The concentration of EDDP formed and the time of formation were determined in microsomes incubated with various concentrations of methadone. EDDP formation was linear for up to 45 rain. EMDP, however, was not detected in these experiments, but low concentrations of EMDP have been detected on a few occasions when 100IJM methadone was used (data not shown). The much slower rate of formation of EMDP under in vitro conditions is consistent with the low concentrations of this metabolite detected in plasma and urine. Furthermore, results from this in vitro study implied that the GC-PICI-MS method was suitable for the study of the in vitro N-demethylation of methadone. Preliminary results of a study on involvement of the role of the cytochrome P450 subtype isozymes in the N-demethylation of methadone have been presented (14) .
Conclusion
The importance of methadone in the treatment of heroin addiction has been a priority of the National Institute on Drug Abuse (NIDA), especially in its expanded research on addiction and women's health (15) . The utility of this method for quantitating methadone, EDDP, and EMDP in human plasma and urine from individuals using or abusing methadone and in human liver microsomes incubated with methadone suggests that it will be useful for most pharmacokinetic, drug monitoring, and toxicity studies designed to assess the effectiveness and safety of this drug. The validation of this GC-PICI-MS method for the analysis of methadone, EDDP, and EMDP in different sample specimens indicates that it is sensitive, reliable, and applicable to the analysis of a variety of biological specimens. Using a solid-phase extraction procedure and a GC-PICI-MS as an analytical method, we have improved upon previously described techniques (10-12) that used lengthy liquid-liquid extractions (several included back extractions) and electron impact ionization that did not include detection of EDDP and EMDP metabolites.
